期刊文献+

新诊断1型糖尿病患者胰岛功能及其影响因素的临床研究 被引量:1

Evaluation and correlates of β-cell function in patients with newly-onset type 1 diabetes mellitus
下载PDF
导出
摘要 目的:探讨新诊断1型糖尿病患者胰岛功能水平及其影响因素。方法 :选取2010年1月—2015年12月在南京医科大学第一附属医院内分泌科住院治疗的新诊断1型糖尿病患者105例,测糖化血红蛋白、胰岛自身抗体及HLA-A和-DR位点,控制血糖<10 mmol/L后行混合餐试验,测血糖、胰岛素及C肽,计算峰值C肽≥0.2 nmol/L的比例,并采用Logistic回归分析影响新诊断1型糖尿病患者胰岛功能的因素。结果:89.5%的患者初诊时峰值C肽≥0.2 nmol/L。初诊年龄≤18岁(OR=0.08,95%CI:0.01~0.90),酮症或酮症酸中毒起病(OR=0.08,95%CI:0.01~0.83),携带高危HLA-A-DRB1基因单倍型(OR=0.07,95%CI:0.01~0.61),胰岛自身抗体阳性数>2(OR=0.10,95%CI:0.01~0.87)者峰值C肽≥0.2 nmol/L率更低。结论 :1型糖尿病患者初诊时仍有部分胰岛功能。因此,胰岛功能不能作为鉴别诊断1型或2型糖尿病的唯一依据。新诊断1型糖尿病患者胰岛功能与初诊年龄、酮症或酮症酸中毒起病、HLA-A-DRB1基因单倍型及胰岛自身抗体有关。 Objective: To describe the levels of residual β-cell function in patients with newly-onset type 1 diabetes mellitus, and investigate factors that may be related. Methods: Data obtained from 105 newly-onset hospitalized type 1 diabetes mellitus patients in the First Affiliated Hospital of Nanjing Medical University from 2010 to 2015. Hemoglobin A1c, islet autoantibodies and HLA-A-DR haplotypes were tested. Mixed-meal tolerance test was carried out until the fasting blood glucose was lower than 10 mmol/L; blood glucose, insulin and C-peptide were measured during the test. The rates of peak C-peptide ≥ 0.2 nmol/L were calculated and logistic regression analyses were performed to explore the influence factors. Results:Eighty-night point five percent of patients had peak C-peptide ≥ 0.2 nmol/L. Logistic regression analyses suggested that factors including age of onset ≤18(OR 0.08,95% CI 0.01-0.90),diabetic ketosis or ketoacidosis onset(OR 0.08,95% CI 0.01-0.83),High-risk HLA-A-DRB1 haplotypes(OR 0.07,95% CI 0.01-0.61),counts of islet autoantibodies 〉2(OR 0.10,95% CI 0.01-0.87) were related to lower rates of peak C-peptide ≥ 0.2 nmol/L. Conclusion: We found that residual β-cell function exists in patients with newly-onset type 1 diabetes mellitus. These data reinforce the inadvisability of using C-peptide alone to differentiate between type 1 diabetes mellitus and other forms of diabetes. We also found that age of onset, diabetic ketosis or ketoacidosis onset, HLA-A-DRB1 haplotypes and islet autoantibodies were associated with β-cell function in patients with newly-onset type 1 diabetes mellitus.
出处 《南京医科大学学报(自然科学版)》 CSCD 北大核心 2017年第5期597-600,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金(81070622,81370939,81670756,81530026) 江苏省“333高层次人才培养工程”(2016-7)
关键词 1型糖尿病 胰岛功能 type 1 diabetes mellitus β-cell function
  • 相关文献

参考文献1

  • 1Jin Liu,Lingling Bian,Li Ji,Yang Chen,Heng Chen,Yong Gu,Bingqin Ma,Wei Gu,Xinyu Xu,Yun Shi,Jian Wang,Dalong Zhu,Zilin Sun,Jianhua Ma,Hui Jin,Xing Shi,Heng Miao,Bing Xin,Yan Zhu,Zhenwen Zhang,Ruifang Bu,Lan Xu,Guangde Shi,Wei Tang,Wei Li,Dongmei Zhou,Jun Liang,Xingbo Cheng,Bimin Shi,Jixiang Dong,Ji Hu,Chen Fang,Shao Zhong,Weinan Yu,Weiping Lu,Chenguang Wu,Li Qian,Jiancheng Yu,Jialin Gao,Xiaoqiang Fei,Qingqing Zhang,Xueqin Wang,Shiwei Cui,Jinluo Cheng,Ning Xu,Guofeng Wang,Guoqing Han,Chunrong Xu,Yun Xie,Minmin An,Wei Zhang,Zhixiao Wang,Yun Cai,Qi Fu,Yu Fu,Shuai Zheng,Fan Yang,Qingfang Hu,Hao Dai,Yu Jin,Zheng Zhang,Kuanfeng Xu,Yifan Li,Jie Shen,Hongwen Zhou,Wei He,Xuqin Zheng,Xiao Han,Liping Yu,Jinxiong She,Mei Zhang,Tao Yang.The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients[J].Science China(Life Sciences),2016,59(9):930-939. 被引量:5

二级参考文献35

  • 1Achenbach P., Warncke K., Reiter J., Naserke H.E., Williams A.J.K., Bingley P.J., Bonifacio E., Ziegler A.G.. Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics. Diabetes, 2004, 53: 384-392.
  • 2Epstein F.H., Atkinson M.A., Maclaren N.K.. The Pathogenesis of Insulin-Dependent Diabetes Mellitus. N Engl J Med, 1994, 331: 1428-1436.
  • 3Baekkeskov S., Aanstoot H.J., Christgai S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen H., Camilli P.D.. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature, 1990, 347: 151-156.
  • 4Beck R.W., Tamborlane W.V., Bergenstal R.M., Miller K.M., DuBose S.N., Hall C.A.. The T1D Exchange Clinic Registry. J Clinical Endocrinology Metabolism, 2012, 97: 4383-4389.
  • 5Besser, R.E., Shields, B.M., Casas, R., Hattersley, A.T., and Ludvigsson, J. (2013). Lessons from the mixed-meal tolerance test. Diabetes Care, 195–201.
  • 6Bingley P.J., Gale E.A.M.. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia, 2006, 49: 881-890.
  • 7Bonifacio E., Lampasona V., Genovese S., Ferrari M., Bosi E.. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol, 1995, 155: 5419-5426.
  • 8Bottazzo G.F., Florin-Christensen A., Doniach D.. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, 1974, 2: 1279-1283.
  • 9Christie M.R., Molvig J., Hawkes C.J., Carstensen B., Mandrup-Poulsen T.. IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin. Diabetes Care, 2002, 25: 1192-1197.
  • 10Eisenbarth G.S.. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med, 1986, 314: 1360-1368.

共引文献4

同被引文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部